Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
Rusfertide’s big readout will now not come until 2025.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.